Skip to main content
SpringerLink
Log in

Diabetes and Osteoporosis

  • Chapter
  • First Online:
Diabetes and Aging-related Complications

Abstract

Accumulating evidence has shown that the risk of osteoporotic fracture is increased in patients with diabetes mellitus independently of bone mineral density. Thus, diabetes-related bone disease is now recognized as one of diabetic complications. Collagen cross-links of advanced glycation end products (AGEs), dysfunction of osteoblasts with low bone turnover, as well as abnormal microstructure of trabecular and cortical bone are involved in bone fragility in diabetes mellitus. Circulating levels of AGEs and homocysteine are increased in patients with diabetes, and AGEs and homocysteine directly inhibited the differentiation of osteoblasts. In addition, these induce the apoptosis and regulate expression levels of sclerostin and RANKL in osteocytes, which play important roles of bone remodeling. Moreover, several antidiabetic drugs affect bone metabolism and fracture risk. Therefore, the underlying mechanism of diabetes-related bone fragility is very complex and not still fully understood. In this review, we described effects of diabetes on bone metabolism and the risk of fracture based on the recent evidence.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int. 2007;18:427–44.

    Article  CAS  PubMed  Google Scholar 

  2. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166:495–505.

    Article  PubMed  Google Scholar 

  3. Yamamoto M, Yamaguchi T, Yamauchi M, Kaji H, Sugimoto T. Diabetic patients have an increased risk of vertebral fractures independent of bone mineral density or diabetic complications. J Bone Miner Res. 2009;24:702–9.

    Article  CAS  PubMed  Google Scholar 

  4. Yamaguchi T, Yamamoto M, Kanazawa I, Yamauchi M, Yano S, Tanaka N, Nitta E, Fukuma A, Uno S, Sho-no T, Sugimoto T. Quantitative ultrasound and vertebral fractures in patients with type 2 diabetes. J Bone Miner Metab. 2001;29:626–32.

    Article  Google Scholar 

  5. Saito M, Fujii K, Mori Y, Marumo K. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int. 2006;17:1514–23.

    Article  CAS  PubMed  Google Scholar 

  6. Yamamoto M, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:1013–9.

    Article  CAS  PubMed  Google Scholar 

  7. Schwartz AV, Garnero P, Hillier TA, Sellmeyer DE, Strotmeyer ES, Feingold KR, Resnick HE, Tylavsky FA, Black DM, Cummings SR, Harris TB, Bauer DC. Health, aging, and body composition study. J Clin Endocrinol Metab. 2009;94:2380–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Farlay D, Armas LA, Gineyts E, Akhter MP, Recker RR, Boivin G. Nonenzymatic glycation and degree of mineralization are higher in bone from fractured patients with type 1 diabetes mellitus. J Bone Miner Res. 2016;31:190–5.

    Article  CAS  PubMed  Google Scholar 

  9. Liu C, Wo J, Zhao Q, Wang Y, Wang B, Zhao W. Association between serum total osteocalcin level and type 2 diabetes mellitus: a systematic review and meta-analysis. Horm Metab Res. 2015;47:813–9.

    Article  CAS  PubMed  Google Scholar 

  10. Kanazawa I, Yamaguchi T, Yamauchi M, et al. Adiponectin is associated with changes in bone markers during glycemic control in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2009;94:3031–7.

    Article  CAS  PubMed  Google Scholar 

  11. Kanazawa I, Yamaguchi T, Yamamoto M, et al. Serum osteocalcin/bone-specific alkaline phosphatase ratio is a predictor for the presence of vertebral fractures in men with type 2 diabetes. Calcif Tissue Int. 2009;85:228–34.

    Article  CAS  PubMed  Google Scholar 

  12. Yamamoto M, Yamauchi M, Sugimoto T. Elevated sclerostin levels are associated with vertebral fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2013;98:4030–7.

    Article  CAS  PubMed  Google Scholar 

  13. Ogawa N, Yamaguchi T, Yano S, Yamauchi M, Yamamoto M, Sugimoto T. The combination of high glucose and advanced glycation end-products (AGEs) inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucose-induced increase in the receptor for AGEs. Horm Metab Res. 2007;39:871–5.

    Article  CAS  PubMed  Google Scholar 

  14. Notsu M, Yamaguchi T, Okazaki K, Tanaka K, Ogawa N, Kanazawa I, Sugimoto T. Advanced glycation end product 3 (AGE3) suppresses the mineralization of mouse stromal ST2 cells and human mesenchymal stem cells by increasing TGF-β expression and secretion. Endocrinology. 2014;155:2402–10.

    Article  PubMed  Google Scholar 

  15. Tanaka K, Yamaguchi T, Kaji H, Kanazawa I, Sugimoto T. Advanced glycation end products suppress osteoblastic differentiation of stromal cells by activation endoplasmic reticulum stress. Biochem Biophys Res Commun. 2013;438:463–7.

    Article  CAS  PubMed  Google Scholar 

  16. Tanaka K, Yamaguchi T, Kanazawa I, Sugimoto T. Effects of high glucose and advanced glycation end products on the expressions of sclerostin and RANKL as well as apoptosis in osteocyte-like MLO-Y4-A2 cells. Biochem Biophys Res Commun. 2015;461:193–9.

    Article  CAS  PubMed  Google Scholar 

  17. Li J, Zhang H, Yan L, Xie M, Chen J. Fracture is additionally attributed to hyperhomocysteinemia in men and premenopausal women with type 2 diabetes. J Diabetes Investig. 2014;5:236–41.

    Article  CAS  PubMed  Google Scholar 

  18. Herrmann M, Tami A, Wildemann B, Wolny M, Wagner A, Schorr H, Taban-Shomal O, Umanskaya N, Ross S, Garcia P, Hubner U, Hermann W. Hyperhomocysteinemia induces a tissue specific accumulation of homocysteine in bone by collagen binding and adversely affects bone. Bone. 2009;44:467–75.

    Article  CAS  PubMed  Google Scholar 

  19. Kanazawa I, Tomita T, Miyazaki S, Ozawa E, Yamamoto LA, Sugimoto T. Bazedoxifene ameliorates homocysteine-induced apoptosis and accumulation of advanced glycation end products by reducing oxidative stress in MC3T3-E1 cells. Calcif Tissue Int. 2017;100(3):286–97.

    Article  CAS  PubMed  Google Scholar 

  20. Takeno A, Kanazawa I, Tanaka K, Notsu M, Yokomoto M, Yamaguchi T, Sugimoto T. Activation of AMP-activated protein kinase protects against homocysteine-induced apoptosis of osteocytic MLO-Y4 cells by regulating the expressions of NADPH oxidase 1 (Nox1) and Nox2. Bone. 2015;77:135–41.

    Article  CAS  PubMed  Google Scholar 

  21. Fulzele K, Riddle RC, DiGirolamo DJ, Cao X, Wan C, Chen D, Faugere MC, Aja S, Hussain MA, Bruning JC, Clemens TL. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell. 2010;142:309–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Yakar S, Rosen CJ, Beamer WG, Ackert-Bicknell CL, Wu Y, Liu JL, Ooi GT, Setser J, Frystyk J, Boisclair YR, LeRoith D. Circulating levels of IGF-I directly regulate bone growth and density. J Clin Invest. 2002;110:771–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Kanazawa I, Yamaguchi T, Sugimoto T. Serum insulin-like growth factor-I is a marker for assessing the severity of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. Osteoporos Int. 2011;22:1191–8.

    Article  CAS  PubMed  Google Scholar 

  24. Burghardt AJ, Issever AS, Schwartz AV, Davis KA, Masharani U, Majumdar Link TM. High-resolution peripheral quantitative computed tomographic imaging of cortical and trabecular bone microarchitecture in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010;95:5045–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Dhaliwal R, Cibula D, Ghosh C, Weinstock RS, Moses AM. Bone quality assessment in type 2 diabetes mellitus. Osteoporos Int. 2014;25:1969–73.

    Article  CAS  PubMed  Google Scholar 

  26. Tanaka K, Kanazawa I, Sugimoto T. Elevated serum pentosidine and decreased serum IGF-I levels are associated with loss of muscle mass in postmenopausal women with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2016;124:163–6.

    CAS  PubMed  Google Scholar 

  27. Tanaka K, Kanazawa I, Sugimoto T. Reduction in endogenous insulin secretion is a risk factor of sarcopenia in men with type 2 diabetes mellitus. Calcif Tissue Int. 2015;97:385–90.

    Article  CAS  PubMed  Google Scholar 

  28. Tanaka K, Kanazawa I, Yamaguchi T, Yano S, Kaji H, Sugimoto T. Active vitamin D possesses beneficial effects on the interaction between muscle and bone. Biochem Biophys Res Commun. 2014;450:482–7.

    Article  CAS  PubMed  Google Scholar 

  29. Tanaka K, Matsumoto E, Higashimaki Y, Katagiri T, Sugimoto T, Seino S, Kaji H. Role of osteoglycin in the linkage between muscle and bone. J Biol Chem. 2012;287:11616–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Qei L, Zillikens MC, Dehghan A, Buitendijk GH, Castano-Betancourt MC, Estrada K, Stolk L, Oei EH, van Meurs JB, Janssen JA, Hofman A, van Leeuwen JP, Witteman JC, Pols HA, Uitterlinden AG, Klaver CC, Franco OH, Rivadeneira F. High bone mineral density and fracture risk in type 2 diabetes as skeletal complications of inadequate glucose control: the Rotterdam Study. Diabetes Care. 2013;36:1619–28.

    Article  Google Scholar 

  31. Schwartz AV, Margolis KL, Sellmeyer DE, Vittinghoff E, Ambrosius WT, Bonds DE, Josse RG, Schnall AM, Simmons DL, Hue TF, Palermo L, Hamilton BP, Green JB, Atkinson HH, O’Connor PJ, Force RW, Bauer DC. Intensive glycemic control is not associated with fractures or falls in the ACCORD randomized trial. Diabetes Care. 2012;35:1525–31.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Kanazawa I, Yamaguchi T, Yamamoto M, Sugimoto T. Relationships between treatments with insulin and oral hypoglycemic agents versus the presence of vertebral fractures in type 2 diabetes mellitus. J Bone Miner Metab. 2010;28:554–60.

    Article  CAS  PubMed  Google Scholar 

  33. Kanazawa I, Yamaguchi T, Yano S, Yamamoto M, Yamauchi M, Kurioka S, Sugimoto T. Baseline atherosclerosis parameter could assess the risk of bone loss during pioglitazone treatment in type 2 diabetes mellitus. Osteoporos Int. 2010;21:2013–8.

    Article  CAS  PubMed  Google Scholar 

  34. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009;180:32–9.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Notsu M, Kanazawa I, Tanaka S, Yamaguchi T, Sugimoto T. Serum dipeptidyl peptidase-4 is associated with multiple vertebral fractures in type 2 diabetes mellitus. Clin Endocrinol. 2016;84:332–7.

    Article  CAS  Google Scholar 

  36. Monami M, Dicembrini I, Antenore A, Mannucci E. Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials. Diabetes Care. 2011;34:2474–6.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Sugimoto T. Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. Biochem Biophys Res Commun. 2008;375:414–9.

    Article  CAS  PubMed  Google Scholar 

  38. Gao Y, Li Y, Xue J, Jia Y, Hu J. Effect of the anti-diabetic drug metformin on bone mass in ovariectomized rats. Eur J Pharmacol. 2010;635:231–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Internal Medicine 1, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan

    Ippei Kanazawa & Toshitsugu Sugimoto

Authors
  1. Ippei Kanazawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Toshitsugu Sugimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ippei Kanazawa .

Editor information

Editors and Affiliations

  1. Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume University School of Medicine, Kurume, Fukuoka, Japan

    Sho-ichi Yamagishi

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Cite this chapter

Kanazawa, I., Sugimoto, T. (2018). Diabetes and Osteoporosis. In: Yamagishi, Si. (eds) Diabetes and Aging-related Complications. Springer, Singapore. https://doi.org/10.1007/978-981-10-4376-5_10

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-4376-5_10

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-4375-8

  • Online ISBN: 978-981-10-4376-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation